Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

Diehl, Volker; Franklin, Jeremy; Pfreundschuh, Michael; Lathan, Bernd; Paulus, Ursula; Hasenclever, Dirk; Tesch, Hans; Herrmann, Richard; Dorken, Bernd; Müller-Hermelink, Hans-Konrad; Dühmke, Eckhardt; Loeffler, Markus
June 2003
New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2386
Academic Journal
Background: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. Methods: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped in 1996 owing to inferior results. Results: For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progression were significantly lower with increased-dose BEACOPP than with COPP-ABVD or standard BEACOPP. Conclusions: Increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD. N Engl J Med 2003;348:2386-95.


Related Articles

  • Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. Aleman, Berthe M.P.; Raemaekers, John M.M.; Tirelli, Umberto; Bortolus, Roberto; van 't Veer, Mars B.; Lybeert, Marnix L.M.; Keuning, Jo J.; Carde, Patrice; Girinsky, Théodore; van der Maazen, Richard W.M.; Tomšič, Radka; Vovk, Marjeta; van Hoof, Achilles; Demeestere, Geertrui; Lugtenburg, Pieternella J.; Thomas, José; Schroyens, Wilfried; De Boeck, Koenraad; Baars, Johanna W.; Kluin-Nelemans, Johanna C. // New England Journal of Medicine;6/12/2003, Vol. 348 Issue 24, p2396 

    Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with...

  • Cancer Chemotherapy Update. Solimando Jr., Dominic A.; Waddell, Aubrey // Hospital Pharmacy;Oct2009, Vol. 44 Issue 10, p858 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and...

  • Impact of first- and second-line treatment for Hodgkin’s lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin’s Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Scholz, M.; Engert, A.; Franklin, J.; Josting, A.; Diehl, V.; Hasenclever, D.; Loeffler, M. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p681 

    Background: Using a parametric carcinogenesis model, we disentangle the superimposing effects of primary and relapse therapies of Hodgkin's disease on secondary neoplasias.Patients and methods: We analyze eight randomized trials of the German Hodgkin's lymphoma study group [5357 individuals, 67...

  • CITATIONS AND CLINICIANS' NOTES: HODGKIN'S LYMPHOMA.  // Current Medical Literature: Leukemia & Lymphoma;2004, Vol. 12 Issue 4, p84 

    Presents citations and clinicians' notes on Hodgkin's lymphoma. Retrospective analysis on the chlorambucil, vinblastine, procarbazine, doxorubicicn, bleomycin, vincristine and etoposide regimen; Relation of the severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated...

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...

  • NEW REGIMENS FOR ADVANCED HODGKIN'S LYMPHOMA -- ACHIEVING CURE AND BALANCING RISKS. Sweetenham, John // Current Medical Literature: Leukemia & Lymphoma;2004, Vol. 12 Issue 4, p73 

    Comments on new therapeutic regimens for advanced Hodgkin's lymphoma. Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone regimen; Stanford V regimen; Prognostic factors and risk-adapted therapy for advanced Hodgkin's lymphoma.

  • Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Niitsu, Nozomi; Okamoto, Masataka; Aoki, Sadao; Okumura, Hirokazu; Yoshino, Tadashi; Miura, Ikuo; Hirano, Masami // Annals of Hematology;Jun2006, Vol. 85 Issue 6, p374 

    Our aim was to study the efficacy of the addition of etoposide and bleomycin to a [cyclophosphamide (CPA), doxorubicin (DXR), vincristine (VCR), and prednisone (PDN)] CHOP-like regimen for the treatment of aggressive lymphoma. The CyclOBEAP regimen was administered over a total period of 12...

  • Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma. Barrington, S. F.; MacKewn, J. E.; Schleyer, P.; Marsden, P. K.; Mikhaeel, N. G.; Qian, W.; Mouncey, P.; Patrick, P.; Popova, B.; Johnson, P.; Radford, J.; O'Doherty, M. J. // Annals of Oncology;Mar2011, Vol. 22 Issue 3, p739 

    Background: Multicentre trials are required to determine how [fluorine-18]-2-fluoro-2-deoxy-D-glucose–positron emission tomography imaging can guide cancer treatment. Consistency in quality control (QC), scan acquisition and reporting is mandatory for high-quality results, which are...

  • Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. DeVita, Vincent T.; Simon, Richard M.; Hubbard, Susan M.; Young, Robert C.; Berard, Costan W.; Moxley, John H.; Frei, Emil; Carbone, Paul P.; Canellos, George P.; DeVita, V T Jr; Simon, R M; Hubbard, S M; Young, R C; Berard, C W; Moxley, J H 3rd; Frei, E 3rd; Carbone, P P; Canellos, G P // Annals of Internal Medicine;May80, Vol. 92 Issue 5, p587 

    The results of treatment of 198 patients with Hodgkin's disease with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) were analyzed. Eighty percent attained complete remission, and 68% of patients achieving a complete remission have remained disease free beyond 10 years from the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics